News | January 27, 2022
Covaxin and Covishield granted conditional market approval
The vaccines are currently only authorised for emergency use in the country
The vaccines are currently only authorised for emergency use in the country
However, these won’t be available at the nearest chemist store soon
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
The Indian government will float a global tender in April 2023 to procure HPV vaccines.
Subscribe To Our Newsletter & Stay Updated
